Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Current Assets (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Current Assets for 16 consecutive years, with $103.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Assets fell 9.06% to $103.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $103.4 million, a 9.06% decrease, with the full-year FY2025 number at $103.4 million, down 9.06% from a year prior.
  • Current Assets was $103.4 million for Q4 2025 at Anika Therapeutics, up from $101.6 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $177.8 million in Q2 2021 to a low of $99.3 million in Q2 2025.
  • A 5-year average of $148.0 million and a median of $159.6 million in 2023 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: rose 7.66% in 2021, then plummeted 35.92% in 2025.
  • Anika Therapeutics' Current Assets stood at $168.5 million in 2021, then increased by 0.6% to $169.5 million in 2022, then dropped by 3.68% to $163.3 million in 2023, then crashed by 30.41% to $113.7 million in 2024, then decreased by 9.06% to $103.4 million in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Current Assets are $103.4 million (Q4 2025), $101.6 million (Q3 2025), and $99.3 million (Q2 2025).